When a company stumbles by keeping spending still too high, has misfortune in Europe although foreseen by drharv, takes 28 months to start a phase 3 then a company is lucky to maintain much market cap. Company was not lucky. Company did not learn from previous RS, should have done more than 16 to 1 so egg in their face deservedly if support found below $3. Still only 4 sites recruiting phase 3, could FDA be demanding a cautious rollout, which is factored in or just likely the typical path to more slippage of dates